- Solutions
Our solutions
- OverviewOur workflow solutions give you the data, tools, and insights to power every decision
- Strategic IntelligenceGet a complete view of strategic issues and stay ahead of emerging disruptive themes
- Sales IntelligenceOur workflow solutions give you the data, tools, and insights to power every decision
- Industry
- Platform
Our platform
Your powerful intelligence platform
Explore the fully comprehensive productivity and insights platform
- Company
We are GlobalData
A second spike of cases was seen in the UK at the start of August, and while the new daily cases are currently increasing at a lower rate than was seen in the first wave, precautionary measures must be taken to prevent them from increasing any further, says GlobalData, a leading data and analytics company. […]
Dr Reddy’s consolidates COVID-19 portfolio with Sputnik V vaccine deal in India, says GlobalData
Following the news that India-based Dr. Reddy’s Laboratories (Dr Reddy’s) has partnered with the Russian Direct Investment Fund (RDIF) to distribute the COVID-19 vaccine Sputnik V in India; Prashant Khadayate, Pharma Analyst at GlobalData, a leading data and analytics company, offers his view: “This is the third deal by Dr Reddy’s for its COVID-19 portfolio […]
World Alzheimer’s Day: Biogen’s aducanumab submission to FDA could change disease landscape
World Alzheimer’s Day 2020 (21 September) serves as a timely reminder that drug development in this space is slow, as the Alzheimer’s disease (AD) drug market in its current form is marked by an overwhelming need for disease modifying therapies (DMTs) and a more diverse set of treatment options for patients who are experiencing cognitive […]
October FDA Advisory Committee meeting on Alkermes’ ALKS-3831 has mixed expectations on weight gain data discussion
Alkermes’ schizophrenia/bipolar disorder candidate ALKS–3831 weight gain data will be at the forefront of a 9 October FDA Advisory Committee (AdCom) meeting, but how the panel members will evaluate it is up for debate, as reported by William Newton, Pharma Writer for the Investigative News team at GlobalData, a leading data and analytics company. Newton comments: “The AdCom will question whether ALKS–3831, which is a combination of an opioid antagonist […]
SGLT-2 inhibitors likely to be primary growth drivers of branded heart failure treatment market, says GlobalData
Eli Lilly and Boehringer Ingelheim’s (BI’s) Jardiance (empagliflozin) and AstraZeneca’s Farxiga (dapagliflozin) are expected to drive heart failure (HF) market growth and achieve high uptake as cardiologists become more familiar with the sodium-glucose cotransporter-2 inhibitors (SGLT-2I) class, says GlobalData, a leading data and analytics company. At the recently concluded European Society of Cardiology (ESC) Congress […]
Amarin’s positive ESC data may boost Vascepa’s EU marketing efforts amid US generic entry threat
Amarin Corporation recently presented final results from the EVAPORATE trial in which Vascepa (icosapent ethyl) reduced patients’ coronary plaque by 17% compared to placebo following 18 months. The newly presented results can be leveraged to reinforce physician education and maximize revenue opportunity in the EU where Amarin is not facing imminent market exclusivity loss, according to GlobalData, a […]
More public pharma and CMOs took PPP COVID-19 small business loans
At least 99 publicly owned pharma companies and contract manufacturing organizations (CMOs) – many with substantial market value and access to capital markets – were approved to receive PPP loans that were intended to help small businesses in the US to pay workers during the COVID-19 pandemic, a GlobalData analysis of a partial release of information by the Small Business Administration (SBA) shows. PPP (paycheck protection program) loans are a US federal government initiative. Fiona Barry, Associate Editor of GlobalData PharmSource, […]
Despite crowded CKD-HPT market, Shield Therapeutics remains committed to PT20 following positive Phase IIb results
Phase IIb results were published in July for Shield Therapeutics’ oral iron-based phosphate binder PT20 for the treatment of hyperphosphatemia (HPT) in dialysis-dependent chronic kidney disease (CKD) patients. Although the CKD-HPT market has several marketed treatments available, PT20 has the potential to capture a slice of the HPT market by targeting dialysis-dependent patients who are […]
Roche’s Ocrevus confirm its strong position of highly efficacious drug in the MS landscape
Following the publication of new positive data from the Phase IIIb CASTING trial of Roche’s Ocrevus (ocrelizumab) in patients with relapsing-remitting multiple sclerosis (RRMS); Alessio Brunello, Managing Pharma Analyst at GlobalData, a leading data and analytics company, offers his view: “Roche’s Ocrevus has several notable clinical attributes that support its strong market uptake, including high […]
Top 20 global innovative pharmaceutical companies by MCap saw 10.2% rise in MCap in Q2 2020, says GlobalData
Many pharmaceutical companies have performed well, despite the impact of COVID-19, as all of the top 20 global innovative bio/pharma companies, ranked by market capitalization (MCap), reported an increase in MCap for the quarter ended 30 June 2020 (Q2 2020). As a whole, the group reported an increase of 10.2% with an aggregate MCap of […]
Inovio’s COVID-19 vaccine outcome will affect future of other DNA-based pipeline assets, says GlobalData
Inovio was one of the first of the over 200 companies to enter the pre-clinical development of a prophylactic COVID-19 vaccine (INO-4800), but the progress of any other program threatens Inovio’s success and market capitalization and INO-4800 could contribute up to 90% of Inovio’s revenue in 2022. The success or failure of INO-4800 will have […]
Key players in IBD space engage effectively with Japanese patients through well-established digital strategy, says GlobalData
In Japan, the treatment landscape for inflammatory bowel disease (IBD), comprising Crohn’s disease (CD) and ulcerative colitis (UC), is mature and encompassing many conventional therapies as well as novel therapies including biologics and a small molecule. With the increasing competition from biosimilars and the late-stage pipeline drugs, key players with novel therapies are offering comprehensive […]
Biosimilars market could be strengthened by informing payers and patients of biological therapy advantages
The US biosimilar drugs market has failed to deliver on the promise of making biologics more affordable and widespread. The education of all sectors of this market is a key factor that will drive increased uptake and provide much-needed savings for patients during these turbulent economic times. While at the same time strengthening the biosimilar […]
E-pharma set to revolutionize drug market access in India as COVID-19 drives e-commerce growth, says GlobalData
The COVID-19 induced lockdown resulted in an unprecedented rise in e-commerce transactions across India. In line with this, e-pharma sector also witnessed growth despite regulatory challenges. Against this backdrop, e-pharma space is all set to revolutionize drug market access in the country, says GlobalData, a leading data and analytics company. Anupama Mishra, Pharma Analyst at […]
Neovascularization inhibitor sales will near $7bn in diabetic retinopathy market in 2029, says GlobalData
The diabetic retinopathy (DR) market has been dominated by neovascularization inhibitors, and this group of therapies is expected to generate more than $6.8bn in sales in the DR market in 2029, rising from $3.2bn in 2019 at a compound annual growth rate (CAGR) of 7.8%. This increase is expected to be driven by the demonstrable […]
Few CMOs are equipped to manufacture cell and gene therapies
As more than 7,000 cell and gene therapies progress through the development pipeline and only 152 CMOs have the capabilities to manufacture them, production bottlenecks are the major obstacle to large-scale commercial manufacture once more Advanced Therapy Medicinal Products (ATMPs) are approved, says GlobalData, a leading data and analytics company. Currently, 79 of these cell […]
Three-quarters of specialists increased use of telemedicine during COVID-19 pandemic
A total 73% of cardiology, gastroenterology, pulmonology, and respiratory specialists in the US, Europe, the UK and Japan indicated that their use of telemedicine has increased as a result of the pandemic, according to a survey by data and analytics firm GlobalData. Kathryn Whitney, MSc, Director of Thematic Analysis at GlobalData, comments: “Approximately two-thirds of […]
Brazil’s high COVID-19 case count allows for clinical trials to progress, says GlobalData
While the COVID-19 pandemic continues to cause high numbers of confirmed new cases in Brazil, the patient population available for the increasing number of COVID-19 clinical trials should allow these to continue to completion, says GlobalData, a leading data and analytics company. Scotty Chung-Siu, MPH, Senior Analyst at GlobalData, comments: “The number of COVID-19 cases […]
Small-cap companies have 85% of the COVID-19 pipeline of small-cap and mid-cap candidates
A total of 198 small- and mid-cap Bio/Pharma companies are currently involved in vaccine or therapeutic development for COVID-19, with a total of 244 unique candidates in the pipeline from these companies. Of these, small-cap companies have the largest proportion of the pipeline candidates for COVID-19 (85%), either the discovery or preclinical stages. This indicates […]
Sanofi impacted by disrupted clinical trials and lagging vaccine development due to COVID-19, says GlobalData
Sanofi’s progress in research and development (R&D) has been adversely impacted by the COVID-19 pandemic. As of late August, six of Sanofi’s clinical trials, which were being conducted in 31 countries, have been disrupted, with most of the disruptions being in Phase II and III – including two pivotal trials. These delays will impact regulatory […]